DV
Dividend Vision

PRLD — Prelude Therapeutics Inc

Prelude Therapeutics Inc (PRLD)

Total return is -78.8% over the past 5.9 years, 234.2 points behind SPY at 155.4%. Its deepest 1-year drawdown was 70.1%.

This appears to be a single-stock equity holding rather than a diversified ETF. Prelude Therapeutics Inc is a biopharmaceutical company, and the listing lacks standard ETF characteristics such as an expense ratio, distribution rate, or specified fund objective. As a single equity security, it carries company-specific risk without the diversification benefits typical of ETFs, and it does not function as an income-generating investment through distributions.

PRLD key facts

Asset type
Stock
Asset class
Equity
Inception date
09/25/2020
Last close
$5.55
Market cap
$323,359,936
Average volume
452100.0
Beta
0.948
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.96